Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology

References

• Boltjes A, Movita D, Boonstra A, et al. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014;61:660–671.
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Iredale JP. Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution. J Hepatol. 2012;56:1417–1419.
   PubMed Web of Science ®Google Scholar
• Dultz G, Gerber L, Zeuzem S, et al. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients. J Viral Hepat. 2016;23:267–273.
   PubMed Web of Science ®Google Scholar
• Kazankov K, Barrera F, Moller HJ, et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology. 2014;60:521–530.
   PubMed Web of Science ®Google Scholar
• Gronbaek H, Sandahl TD, Mortensen C, et al. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther. 2012;36:173–180.
   PubMed Web of Science ®Google Scholar
• Holland-Fischer P, Gronbaek H, Sandahl TD, et al. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut. 2011;60:1389–1393.
   PubMed Web of Science ®Google Scholar
• Rode A, Nicoll A, Moller HJ, et al. Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. Gut. 2013:62:1231–1232.
   PubMed Web of Science ®Google Scholar
• Moller HJ, Gronbaek H, Schiodt FV, et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol. 2007;47:671–676.
   PubMed Web of Science ®Google Scholar
• Sandahl TD, Gronbaek H, Moller HJ, et al. Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: a prospective cohort study. Am J Gastroenterol. 2014;109:1749–1756.
   PubMed Web of Science ®Google Scholar
• Grønbaek H, Rødgaard-Hansen S, Aagaard NK, et al. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). J Hepatol. 2016;64:813–822.
   PubMed Web of Science ®Google Scholar
• Laursen TL, Wong GL, Kazankov K, et al. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. J Gastroenterol Hepatol. 2018;33:484–491.
   PubMed Web of Science ®Google Scholar
• Mascia C, Vita S, Zuccala P, et al. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One. 2017;12:e0179400.
   PubMed Web of Science ®Google Scholar
• Andersen ES, Rodgaard-Hansen S, Moessner B, et al. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study. Eur J Clin Microbiol Infect Dis. 2014;33:117–122.
   PubMed Web of Science ®Google Scholar
• Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 2009;252:595–604.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293.
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325.
   PubMed Web of Science ®Google Scholar
• Moller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest. 2002;62:293–299.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
   PubMed Web of Science ®Google Scholar
• Cleo Study G, Ascione A, Adinolfi LE, et al. Boceprevir or telaprevir in hepatitis C virus chronic infection: the Italian real life experience. World J Hepatol. 2016;8(22):949–56
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153–194.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62:79–86.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–1505.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–1135.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Horiike N, Akbar SMF, et al. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol. 2005;40:52–56.
   PubMed Web of Science ®Google Scholar
• Deterding K, Honer Zu Siederdissen C, Port K, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42:889–901.
   PubMed Web of Science ®Google Scholar
• Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103:2776–2783.
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313.
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692–699.
   PubMed Web of Science ®Google Scholar
• Karlas T, Benckert J, Beer S, et al. Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy? Aliment Pharmacol Ther. 2016;43:543–544.
   PubMed Web of Science ®Google Scholar
• Brady MT, MacDonald AJ, Rowan AG, et al. Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol. 2003;33:3448–3457.
   PubMed Web of Science ®Google Scholar
• Mengshol JA, Golden-Mason L, Arikawa T, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One. 2010 ;5:e9504.
   PubMed Web of Science ®Google Scholar
• Tu Z, Pierce RH, Kurtis J, et al. Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. Gastroenterology. 2010;138:305–314.
   PubMed Web of Science ®Google Scholar
• Liaskou E, Zimmermann HW, Li KK, et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology. 2013;57:385–398.
   PubMed Web of Science ®Google Scholar
• Burgio VL, Ballardini G, Artini M, et al. Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C virus etiology. Hepatology. 1998;27:1600–1606.
   PubMed Web of Science ®Google Scholar
• Dolganiuc A, Norkina O, Kodys K, et al. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology. 2007;133:1627–1636.
   PubMed Web of Science ®Google Scholar
• Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol. 2007;82:479–487.
   PubMed Web of Science ®Google Scholar
• Hosomura N, Kono H, Tsuchiya M, et al. HCV-related proteins activate Kupffer cells isolated from human liver tissues. Dig Dis Sci. 2011;56:1057–1064.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011;141:1220–1230.
   PubMed Web of Science ®Google Scholar
• Liu BS, Groothuismink ZM, Janssen HL, et al. Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections. J Leukoc Biol. 2011;89:981–988.
   PubMed Web of Science ®Google Scholar
• Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005;115:56–65.
   PubMed Web of Science ®Google Scholar
• Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci. 2002;7:d793–d807.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest. 1989;84:1780–1785.
   PubMed Web of Science ®Google Scholar